List view / Grid view
Pfizer has announced its acquisition of ReViral to advance disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus infections and prevent illness through vaccination.
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Eddy Littler said, “I am pleased to be joining at this critical time where I can help move the lead programme RV521 forward into clinical development...
8 September 2015 | By Victoria White
The funding will enable ReViral to progress its lead drug candidate, RV521, into proof of concept clinical trials and to continue the development of a novel series of antiviral inhibitors...
4 December 2014 | By reViral
Second tranche of Seeding Drug Discovery award from Wellcome Trust Innovations...
